Anti-Müllerian Hormone (AMH) reflects primordial follicle pool size and is the best singl...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-AMH-OVARIAN-RESERVE-BSO-TIMING |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-05-18 | actionability review required |
| Diseases | DIS-OVARIAN |
| Sources | SRC-NCCN-GENETIC-FAMILIAL-BREAST-OVARIAN-2025 |
Actionability Facts
| Biomarker | BIO-AMH-OVARIAN-RESERVE |
|---|---|
| Variant | Anti-Müllerian Hormone — ovarian reserve / BSO timing counselling in BRCA1/2 carriers |
| Disease | DIS-OVARIAN |
| ESCAT tier | X |
| Recommended combinations | BRCA1/2 carrier pre-BSO fertility counselling: AMH + antral follicle count + age determines oocyte cryopreservation feasibility, BRCA1: BSO at 35-40 after childbearing complete; BRCA2: 40-45, Post-BSO menopausal-hormone-therapy decision: consider until natural menopause age (50-51) in carriers without prior breast cancer, per NCCN Genetic 2025 + Domchek 2014 |
| Contraindicated monotherapy | AMH must NOT be used as an ovarian cancer screening test or as a basis to delay BSO beyond NCCN-recommended age in confirmed BRCA1/2 carriers |
| Evidence summary | Anti-Müllerian Hormone (AMH) reflects primordial follicle pool size and is the best single biomarker of ovarian reserve. In the BRCA1/2 carrier population, AMH is used as DECISION-SUPPORT for risk-reducing salpingo-oophorectomy (RSSO / BSO) timing, fertility counselling, and oocyte cryopreservation planning — NOT as a screening test for ovarian cancer. NCCN Genetic/Familial Breast/Ovarian 2025 recommends BSO at age 35-40 (BRCA1) / 40-45 (BRCA2) after completion of childbearing. AMH is one input informing the personalised cost/benefit of pre-BSO oocyte cryopreservation and post-BSO menopausal hormone replacement decisions. AMH does NOT predict ovarian cancer risk and does NOT replace germline-mutation-driven BSO recommendation. ESCAT X — AMH does not drive cancer-treatment selection; categorised as reproductive-counselling support. |
Notes
STUB pending two-Co-Lead signoff. A dedicated IND-BRCA-CARRIER-FERTILITY-PRESERVATION Indication entity (gated on age + reproductive intent) would be the cleanest home for this biomarker; the listed surveillance Indications are adjacent but not precisely fitted to the fertility-counselling use case. Engine must explicitly de-couple BSO timing from AMH value — AMH never delays BSO in a confirmed carrier; it only informs WHETHER to attempt oocyte cryopreservation before BSO and HOW many cycles to plan.
Used By
No reverse references found in the YAML corpus.